Reviva Pharmaceuticals Holdings, Inc. said cash and cash equivalents were approximately $17.5 million as of September 30, 2026, but current cash would not satisfy operating needs for 12 months, raising substantial doubt about its ability to continue as a going concern.
RVPH · Reviva Pharmaceuticals Holdings, Inc. · Documents
Substantial doubt about the company's ability to continue as a going concern.
“These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date the consolidated financial statements are issued.”View the 10-Q filed Nov 13, 2026
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →
Reviva reported a net loss of approximately $2.3 million, or $0.17 per share, for the three months ended September 30, 2026. FDA feedback on brilaroxazine is expected Q4 2026, and RECOVER-2 enrollment is targeted for 1H 2027, subject to additional financing.
Reviva Pharmaceuticals Holdings, Inc. effected a one-for-twenty reverse stock split effective March 9, 2026, then closed a public offering on March 20, 2026 that generated approximately $8.9 million in net proceeds.
At its December 18, 2026 meeting, Reviva Pharmaceuticals Holdings, Inc. will seek five director elections and approval of a reverse split from one-for-two (1:2) to one-for-one hundred (1:100). The board could implement it by December 31, 2027 without further approval.
Reviva Pharmaceuticals Holdings, Inc. asks stockholders to authorize a reverse stock split ranging from one-for-two (1:2) to one-for-one hundred (1:100) before December 31, 2027.
Reviva Pharmaceuticals Holdings, Inc. said biliroxazine showed sustained schizophrenia efficacy and plans a second phase three study with top-line data in mid-2028 and an NDA filing in end of 2028 or early Q1, 2029.